Differences in Survival Improvement Between Known and Unknown Primary Merkel Cell Carcinoma in the Era of Immune Checkpoint Inhibitors
收藏NIAID Data Ecosystem2026-05-10 收录
官方服务：
资源简介：
Supplementary materials for the article titled “Differences in Survival Improvement Between Known and Unknown Primary Merkel Cell Carcinoma in the Era of Immune Checkpoint Inhibitors” Patient Consent: All data were de-identified and publicly available, thus the study was exempt from institutional review board approval and informed consent. Finding: Overall, our findings suggest that ICIs may confer greater benefit in KPMCC than in UPMCC.
创建时间：
2025-10-01
